Skip to main content

ALK Gene Rearrangement and PD-L1 Expression

Videos - Lung Cancer
Dr. Edward Garon does not believe there is much value in utilizing PD-L1 inhibitors for pateints with ALK gene rearrangement.
Related Items
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
Phoebe Starr
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology published on August 9, 2021 in Conference Highlights ASCO, Lung Cancer
Patients with Lung Cancer Distressed About Impact of COVID-19 on Access to Care
Walter Alexander
Web Exclusives published on May 28, 2021 in COVID-19, Lung Cancer
EGFR Most Common Mutation in Women with Lung Cancer and No Smoking History
Walter Alexander
Web Exclusives published on May 28, 2021 in Lung Cancer
Tagrisso Approved as Adjuvant Therapy for NSCLC with EGFR Mutations
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology published on February 24, 2021 in FDA Approvals, Lung Cancer
Adjuvant Osimertinib a Practice-­Changing Treatment in Early-Stage NSCLC with EGFR Mutation
Wayne Kuznar
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology published on August 17, 2020 in Lung Cancer
Last modified: August 30, 2021